• +1-646-491-9876
    • +91-20-67278686

    Search

    Fragile X Syndrome - Pipeline Review, H1 2017

    Fragile X Syndrome - Pipeline Review, H1 2017

    • Report Code ID: RW0001767499
    • Category Pharmaceuticals
    • No. of Pages 108
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Fragile X Syndrome - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

    Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Fragile X Syndrome - Overview 6
    Fragile X Syndrome - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 10
    Products under Development by Companies 11
    Products under Development by Universities/Institutes 13
    Fragile X Syndrome - Therapeutics Assessment 14
    Assessment by Target 14
    Assessment by Mechanism of Action 16
    Assessment by Route of Administration 18
    Assessment by Molecule Type 20
    Fragile X Syndrome - Companies Involved in Therapeutics Development 22
    Aelis Farma SAS 22
    AMO Pharma Ltd 22
    Anavex Life Sciences Corp 23
    Confluence Pharmaceuticals LLC 23
    DRI Biosciences Corp 24
    Eli Lilly and Company 24
    Fulcrum Therapeutics Inc 25
    GlaxoSmithKline Plc 25
    GW Pharmaceuticals Plc 26
    Marinus Pharmaceuticals Inc 26
    Neuren Pharmaceuticals Ltd 27
    Neuron Biopharma SA 27
    Ovid Therapeutics Inc 28
    Sage Therapeutics Inc 28
    Zynerba Pharmaceuticals Inc 29
    Fragile X Syndrome - Drug Profiles 30
    acamprosate calcium - Drug Profile 30
    ACT-01 - Drug Profile 31
    AMO-01 - Drug Profile 32
    ANAVEX-273 - Drug Profile 34
    Bryostatin-1 - Drug Profile 44
    cannabidiol - Drug Profile 49
    cercosporamide - Drug Profile 54
    Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 56
    flindokalner - Drug Profile 57
    gaboxadol - Drug Profile 58
    ganaxolone - Drug Profile 60
    JRP-655 - Drug Profile 67
    NNZ-2591 - Drug Profile 68
    NST-0076 - Drug Profile 70
    SAGE-217 - Drug Profile 71
    SGE-872 - Drug Profile 74
    Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile 75
    Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile 76
    Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile 77
    Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile 78
    Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile 79
    Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile 80
    Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 81
    SRT-278 - Drug Profile 82
    TC-2153 - Drug Profile 83
    trofinetide - Drug Profile 84
    Fragile X Syndrome - Dormant Projects 92
    Fragile X Syndrome - Discontinued Products 94
    Fragile X Syndrome - Product Development Milestones 95
    Featured News & Press Releases 95
    Appendix 105
    Methodology 105
    Coverage 105
    Secondary Research 105
    Primary Research 105
    Expert Panel Validation 105
    Contact Us 105
    Disclaimer 106

    List of Tables

    Number of Products under Development for Fragile X Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Fragile X Syndrome - Pipeline by Aelis Farma SAS, H1 2017
    Fragile X Syndrome - Pipeline by AMO Pharma Ltd, H1 2017
    Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2017
    Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H1 2017
    Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H1 2017
    Fragile X Syndrome - Pipeline by Eli Lilly and Company, H1 2017
    Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H1 2017
    Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
    Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2017
    Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
    Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
    Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H1 2017
    Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H1 2017
    Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H1 2017
    Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
    Fragile X Syndrome - Dormant Projects, H1 2017
    Fragile X Syndrome - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Fragile X Syndrome - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Fragile X Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aelis Farma SAS
    AMO Pharma Ltd
    Anavex Life Sciences Corp
    Confluence Pharmaceuticals LLC
    DRI Biosciences Corp
    Eli Lilly and Company
    Fulcrum Therapeutics Inc
    GlaxoSmithKline Plc
    GW Pharmaceuticals Plc
    Marinus Pharmaceuticals Inc
    Neuren Pharmaceuticals Ltd
    Neuron Biopharma SA
    Ovid Therapeutics Inc
    Sage Therapeutics Inc
    Zynerba Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//fragile-x-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//fragile-x-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//fragile-x-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments